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Background/aim: The identification of Candida species isolated from clinical specimens provides information about antifungal
susceptibility and sheds light on the choice of empirical treatment. In the present study, restriction enzyme analysis of C. albicans and
non-albicans Candida species previously identified by conventional methods was done to evaluate the utility of restriction enzyme
analysis for more rapid and reliable identification of Candida species.
Materials and methods: A total of 146 Candida strains isolated from various clinical specimens and ATCC strains were included. PCR
products were digested with MwoI for all species and with BslI for C. parapsilosis and C. tropicalis strains.
Results: The strains were identified by conventional methods as 40 C. albicans, 27 C. parapsilosis, 26 C. tropicalis, 25 C. glabrata, 11 C.
kefyr, 10 C. krusei, and 7 C. guilliermondii strains. Restriction digestion with MwoI was able to distinguish between five different species
(C. albicans, C. krusei, C. guilliermondii, C. kefyr, and C. glabrata), while BslI digestion could distinguish between C. tropicalis and C.
parapsilosis.
Conclusion: Restriction enzyme analysis with MwoI and BslI can be used for the identification of Candida species in situations where
rapid identification is necessary or conventional methods are problematic.
Key words: Candida species, identification, restriction enzyme analysis

1. Introduction
The frequency of invasive fungal infections has increased
substantially during the past two decades and it has
become a major cause of morbidity and mortality in
immunocompromised patients. Aspergillosis, candidiasis,
cryptococcosis, and zygomycosis are the main invasive
fungal infections observed in these patients (1). Among
the fungal pathogens, Candida species are the most
common cause of invasive fungal infections (2,3).
Candida species rank as the fourth most common
cause of nosocomial bloodstream infections and the
mortality of these infections varies between 33% and
75%. Despite the widespread use of antifungals for
prophylaxis and treatment of invasive fungal infections
in immunocompromised patients, candidemia remains
the most frequent life-threatening fungal disease and is
associated with a prolonged hospital stay that results in a
rise in costs (4–6).
Although Candida albicans is still the most common
cause of Candida infections, fluconazole prophylaxis
decreased the incidence of C. albicans infections, but
* Correspondence: reyhanyis@yahoo.com

1058

this caused an increase in the incidence of non-albicans
Candida species like fluconazole-resistant C. glabrata
and C. krusei (1,5,7). Increasing incidence of candidemia
caused by C. parapsilosis, C. glabrata, C. tropicalis, C. krusei,
C. guilliermondii, and C. lusitaniae was also reported.
Approximately half of the reported cases of candidemia
are now caused by non-albicans Candida species. This
has been attributed to the use of fluconazole prophylaxis
(8–12).
Rapid identification of Candida species isolated from
clinical specimens gives information about antifungal
susceptibility as well as shedding light on the choice of
empirical treatment. For these reasons, rapid, reliable,
and accurate identification of isolates is very important.
Identification methods such as germ tube test, morphology
on Corn Meal Agar with Tween 80, and assimilationfermentation reactions used for the identification of
Candida species in routine laboratory settings are timeconsuming and may lead to ambiguous results, but on
the other hand genotype-based methods have become of
interest in recent years (12,13).
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In the past years, many genotypical methods have
been used for rapid identification of Candida species.
Molecular approaches including PCR, ITS fragment
length polymorphism, restriction fragment length
polymorphism, DNA probe hybridization, DNA
sequencing, and new techniques like MALDI-TOF MS
are used as alternatives to the traditional phenotypic
methods. Polymerase chain reaction-restriction enzyme
analysis (PCR-REA) of ITS rDNA is a rapid, easy, and
cost-effective method used for the identification of
Candida species (13–16).
The aim of this study was to apply REA for rapid
and reliable identification of Candida albicans and nonalbicans Candida species isolated from clinical specimens
that had been previously identified by conventional
methods and to compare the results.
2. Materials and methods
2.1. Isolates
A total of 146 Candida strains (40 C. albicans, 27 C.
parapsilosis, 26 C. tropicalis, 25 C. glabrata, 11 C. kefyr, 10
C. krusei, and 7 C. guilliermondii) isolated from various
clinical specimens at the Dokuz Eylül University Hospital
Mycology Laboratory were included in the study. C.
albicans ATCC 14053, C. parapsilosis ATCC 90018, and
C. krusei ATCC 6258 were used as quality-control strains.
All isolates were kept at –80 °C in 50% glycerol and
brain-heart infusion broth as stock cultures. The strains
that were subcultured onto Sabouraud dextrose agar were
incubated at 37 °C for 48 h. The isolates were identified by
using conventional methods and then by PCR-REA.
2.2. Identification methods
All strains were identified according to the germ tube
test, morphology on Corn Meal Agar with Tween 80,
CHROMagar Candida (CHROMagar, France), and the
API 20C AUX (BioMérieux, France) automatized system.
2.3. Polymerase chain reaction-restriction enzyme
analysis
2.3.1. Polymerase chain reaction (PCR)
Pure cultures of each isolate were grown in yeast extract
peptone dextrose (YPD) agar (Difco, USA) at 37 °C for 48
h and in 5 mL of YPD broth (Difco) at 37 °C for 24 h (17).
DNA extraction of all Candida strains was performed with
the NucleoSpin Tissue Kit (Macherey-Nagel, Germany)
according to the manufacturer’s recommendations.
Primers
[forward:
primer
1
(5’-GTCAAACTTGGTCATTTA-3’), reverse: primer 3
(5’-TTCTTTTCCTCCGCTTATTGA-3’)] were selected
to allow the amplification of the target internal transcribed
spacer region 1 (ITS1), 5.8S rDNA, and ITS2 (13).
A reaction volume of 100 µL consisting of 10 µL of
10X Taq DNA polymerase buffer (MBI Fermentas EPO

402), 2 µL of 0.2 mM dNTP (Intron Biotechnology
32111), 6 µL of 1.5 mM MgCl2 (MBI Fermentas EPO 402),
1 µL each of 20 pmol forward + reverse primer (primers 1
and 3, Alpha DNA 191336 and 191337), 5 U/µL Taq DNA
polymerase (MBI Fermentas EPO 402) (5 U/µL), 10 µL of
Candida DNA, and water were used (13).
PCR cycles consisted of a denaturation step at 94 °C for
30 s, an annealing step at 50 °C for 30 s, and an extension
step at 72 °C for 1 min. After the initial denaturation of
DNA at 94 °C for 3 min and final extension at 72 °C for
10 min, 34 cycles were performed (13). The PCR products
were analyzed by electrophoresis on 2% agarose gels and
stained with ethidium bromide. The Gene Ruler 100-bp
DNA Ladder Mix (MBI Fermentas SM0321) was used
as the DNA marker (13). The gels were visualized with
Syngene GeneSnap (Synoptics Ltd., USA).
2.3.2. Restriction enzyme analysis (REA)
PCR products were purified using the PCR Clean-Up
Kit (GeneMark DP04) according to the instructions of
the manufacturer. Then REA was applied to all strains.
All strains were digested with REA by using MwoI (5’...G
C N N N N N↓N N G C...3’). Because C. tropicalis and
C. parapsilosis strains could not be discriminated after
digestion with MwoI, further REA was performed by
using the BslI (5’...C C N N N N N↓N N G G...3’) enzyme.
Restriction analysis was performed with 12 µL of
purified PCR product and 1 U of the respective enzyme
[MwoI (neoschizomer of HpyF10VI) (Fermentas ER1731
/300U) or BslI (isoschizomer of BseLI-BsiYI) (Fermentas
ER1202 /2500U)] at 37 °C for 2 h for MwoI and at 55 °C
for 45 min for BslI (13).
Restriction
fragments
were
separated
by
electrophoresis in 2% agarose gel at 120 V for 40 min.
An O’RangeRuler 50-bp DNA Ladder (MBI Fermentas
SM0613) was used as a DNA marker. The gels were stained
with ethidium bromide and visualized with Syngene
GeneSnap (Synoptics Ltd., USA).
2.4. Statistical analysis
REA band patterns of the Candida strains were compared
with the findings of Trost et al. (13). The identification
of 146 Candida strains by germ tube test, morphology
on Corn Meal Agar with Tween 80, CHROMagar
Candida (CHROMagar, France), and the API 20C AUX
automatized system (BioMérieux, France) were accepted
as the reference methods for the determination of
sensitivity, specificity, and positive and negative predictive
values of REA since these identification procedures
are mainly performed in routine clinical laboratories.
Sensitivity, specificity, positive and negative predictive
values, and confidence intervals of REA for identification
of the Candida species were determined with Epi Info
6.04 (http://www.cdc.gov/epiinfo/Epi6/ei6.htm).
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2.5. DNA sequencing
Sequence analysis was performed for four C. albicans
isolates that resulted in different restriction patterns and
two C. albicans isolates that produced three bands with
the same enzyme. C. albicans ATCC 14053 was used
as the quality control strain for sequence analysis. DNA
sequencing was also performed for two C. guilliermondii
isolates that showed different REA patterns and two of five
C. guilliermondii isolates, all of which showed the same
restriction patterns. The PCR products from different
isolates were sequenced on both strands using PCR primers
1 and 3. The PCR products of these selected strains were
purified with the PCR Clean-Up Kit (GeneMark DP04) and
directly sequenced using the DYEnamic ET Terminator
Cycle Sequencing Kit (Amersham) by İontek (Turkey) in
an ABI PRISM 310 Genetic Analyzer. Sequence analysis
results were evaluated with Bio-Edit version 7.0.
2.6. Phylogenetic analysis
Molecular Evolutionary Genetics Analysis (MEGA)
software version 4.0 (http://www.megasoftware.net) was
used for the phylogenetic analysis of the C. guilliermondii
strains that were sequenced and the C. guilliermondii and
C. membranaefaciens strains that were downloaded from
GenBank (GenBank accession numbers: AM176631,
AM176630,
AM176629,
AM176628,
AB260136,
AB260135,
AM176626,
AM176627,
AB032176,
AM117815, AB054109, AM160625, AJ585348, and
AJ539367, respectively).
3.Results
3.1. Results of conventional identification methods
The isolates were identified as 40 C. albicans, 27 C.
parapsilosis, 26 C. tropicalis, 25 C. glabrata, 11 C. kefyr,
10 C. krusei, and 7 C. guilliermondii by the conventional
methods mentioned above.
3.2. Results of REA
The PCR products of C. albicans, C. parapsilosis, C. tropicalis,
C. glabrata, C. kefyr, C. krusei, and C. guilliermondii isolates
were 586 bp, 570 bp, 576 bp, 925 bp, 800 bp, 560 bp, and
657 bp, respectively. The PCR products of 146 Candida
isolates were digested with MwoI enzyme. Figure 1 shows a
2% agarose gel image of one representative isolate of seven
Candida species restricted with MwoI (Figure 1a). Further
REA was performed by using BslI for C. tropicalis and C.
parapsilosis strains (Figure 1b).
Sizes of ITS1-ITS2 products for Candida species before
and after digestion with MwoI and BslI are shown in Table 1.
Thirty-six of 40 C. albicans isolates produced a REA
pattern with three bands of 141, 184, and 261 bp while
four of them produced four bands of 184 bp, 141 bp,
approximately 165 bp, and 95 bp (Figure 2).
The restriction of C. parapsilosis and C. tropicalis
strains with MwoI resulted in three 336-, 146-, and 88-
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bp and 325-, 154-, and 97-bp fragments, respectively. In
order to distinguish these two species, further restriction
was performed with the BslI enzyme and the lengths of
REA products were 413, 94, and 63 bp for C. parapsilosis
and 326, 187, and 63 bp for 23 of 26 C. tropicalis isolates
(Figure 3).
Restriction of 25 C. glabrata isolates with the MwoI
enzyme resulted in five bands of 414, 174, 171, 86, and 80
bp. The calculated lengths of REA products with MwoI
enzyme were 370 and 430 for C. kefyr and 289, 134, 83,
and 54 bp for C. krusei isolates, respectively (Figure 4).
Restriction of five of seven C. guilliermondii isolates
with MwoI showed two bands at 355 and 302 bp while
the remaining two strains showed REA patterns with two
bands at 390 and 300 bp (Figure 5).
3.3. Results of statistical analysis
Sensitivity, specificity, and positive and negative predictive
values of REA for identification of the Candida species
were shown in Table 2.
3.4. Results of DNA sequence analysis
Four C. albicans isolates, which produced different
restriction patterns, had point mutations (guanine à
adenine). Due to this point mutation, the 5’...G C N N N N
N↓N N G C...3’ region appeared, which resulted in a third
restriction site for MwoI. As a result, four strains produced
four bands of 184 bp, 141 bp, and approximately 165 bp and
95 bp after restriction with the MwoI enzyme (Figure 6).

Figure 1. a) 1- DNA marker, 2- C. albicans ATCC 14053 (261,
184, 141 bp), 3- C. tropicalis clinical isolate (325, 154, 97 bp),
4- C. parapsilosis ATCC 90018 (336, 146, 88 bp), 5- C. krusei
ATCC 6258 (289, 134, 83, 49 bp), 6- C. guilliermondii clinical
isolate (355, 302 bp), 7- C. kefyr clinical isolate (410, 390 bp), 8C. glabrata clinical isolate (414, 174, 171, 86, 80 bp). b) 1- DNA
marker, 2- C. tropicalis clinical isolate (326, 187, 63 bp), 3- C.
parapsilosis ATCC 90018 (413, 94, 63 bp).
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Figure 2. a) 1 and 7- DNA marker, 2–6- PCR products of C. albicans isolates (isolate nos. 307, 332, 377, 420, 439), 8–12- REA products
of the same isolates obtained by digestion with MwoI enzyme. b) 1 and 7- DNA marker, 2–5- PCR products of C. albicans (isolate nos.
377, 439, 600, 749) (586 bp), 6- PCR products of C. albicans ATCC 14053, 8–11- products of REA with MwoI enzyme (isolate nos. 377,
439, 600, 749), 12- products of REA with MwoI enzyme (C. albicans ATCC 14053).

Figure 3. a) 1, 7, 13- DNA marker, 2–6- PCR products of C. parapsilosis (isolate nos. 730, 739, 742, 744, 745), 8–12- REA products of
the same isolates with MwoI enzyme, 14–18- products of REA with BslI enzyme. b) 1, 7, 13- DNA marker, 2–6- PCR products of C.
tropicalis (isolate nos. 632, 689, 727, 735, 754), 8–12- REA products of the same isolates with MwoI enzyme, 14–18- products of REA
with BslI enzyme.

Figure 4. a) 1 and 7- DNA marker, 2–6- PCR products of C. glabrata, 8–12- products of REA of the same isolate with MwoI enzyme. b)
1 and 9- DNA marker (GeneRuler 100-bp DNA Ladder), 2–7- PCR products of C. kefyr, 10–15- REA products of the same isolate with
MwoI enzyme. c) 1 and 8- DNA marker, 2–6- PCR products of C. krusei, 9–13- REA products of the same isolate with MwoI enzyme.
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Figure 5. 1 and 10- DNA marker, 2–8- PCR products of C.
guilliermondii (isolate nos. 99, 139, 408, 409, 782, 784, 785),
11–17- products of REA of the same isolates with MwoI enzyme.

Sequence analysis of two C. guilliermondii isolates (isolate
nos, 99, 139) showing different REA patterns by MwoI
were 91.0% similar to GenBank C. guilliermondii var.
guilliermondii (AM176631, AM176630, AM176629,
AM176628,
AB260136,
AB260135,
AM176626,
AM176627,
AB032176,
AM117815,
AB054109,
AM160625) and 88.9% similar to C. guilliermondii var.
membranaefaciens (AJ606465, AJ585348, AJ539367)
(Figure 7). The two isolates that showed a different REA
pattern were localized within the group of C. guilliermondii
strains when phylogenetic analysis was performed
(Figure 8). Two C. guilliermondii strains (isolate nos.
408, 409), which showed similar restriction patterns with
other C. guilliermondii strains, had similar nucleotide
configurations with the GenBank strains (Figure 7).
The most common six Candida species (C. albicans,
C. glabrata, C. tropicalis, C. krusei, C. parapsilosis, and C.
guilliermondii) were able to be identified within 33–34 h
with REA by using the MwoI and BslI enzymes.
4. Discussion
In recent years, a number of DNA-based methods have
been developed for the identification of pathogenic fungi
and the diagnosis of fungal infections. PCR-based methods
seem promising in terms of simplicity, sensitivity, and
specificity. Ribosomal genes are popular targets for PCRbased systems. Internal transcribed spacer regions (ITS1
and ITS2) are highly variable sequences that have been
used for the identification of fungi (18). PCR-RFLP of the
5.8S rRNA gene and the two ribosomal internal transcribed
spacers (ITS1 and ITS2) has been shown to be a fast and
simple method for species identification (19). Analysis of
the restriction fragment length polymorphisms (RFLPs)
of PCR products has been reported to be a rapid, simple,
and inexpensive technique that requires only standard
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equipment and provides unambiguous results (13). It is
therefore easily transferable to most diagnostic laboratories
and can be used to identify medically important yeasts
(13). In this study, we aimed to evaluate the effectiveness
of the REA method for identifying Candida albicans and
non-albicans Candida species.
Williams et al. (20) applied PCR and RFLP methods
for the identification of eight Candida species and PCR
allowed the identification of C. guilliermondii, C. glabrata,
and C. kefyr while the remaining species were identified
by RFLP according to their restriction patterns. The Bfal
restriction enzyme was detected as the most reliable
enzyme among three enzymes (HaeIII, BfaI, and DdeI) in
the identification of the Candida species. It was emphasized
that application of BfaI and DdeI enzymes was mandatory
for the identification of Candida species except C. glabrata,
C. kefyr, and C. guilliermondii.
In another study, band patterns obtained following
restriction digestion of the ITS1-5.8SrDNA-ITS2 region by
MspI provided the identification of seven Candida species
including C. albicans, C. krusei, C. glabrata, C. parapsilosis,
C. tropicalis, C. lusitaniae, and C. guilliermondii, which
account for up to 95% of Candida infections (21).
In our study, we used PCR-REA to identify medically
important Candida spp. using the universal primers ITS1
and ITS4 to amplify the ITS1 and ITS2 regions and 5.8S
in the rDNA gene. Thirty-six of the C. albicans strains
produced REA patterns with three bands (141, 184, and
261 bp), while four of the strains produced four bands
(184 bp, 141 bp, and approximately 165 bp and 95 bp). The
restriction of C. parapsilosis and C. tropicalis strains with
the same enzyme resulted in three fragments each (336,
146, and 88 bp and 325, 154, and 97 bp, respectively). In
order to distinguish between these two species, further
restriction was performed with BslI and the lengths of
REA products were 413, 94, and 63 bp for C. parapsilosis
and 326, 187, and 63 bp for C. tropicalis. Restriction of C.
glabrata isolates with MwoI resulted in five bands of 414,
174, 171, 86, and 80 bp. Calculated lengths of REA products
were 370 and 430 for C. kefyr and 289, 134, 83, and 54 bp
for C. krusei isolates. Restriction of five C. guilliermondii
isolates with MwoI showed two bands at 355 and 302 bp
while the remaining two strains showed REA patterns
with two bands at 390 and 300 bp. Additional digestion
with BslI established that these two strains showed totally
different restriction patterns from the other five strains.
PCR-RFLP is a rapid and reliable method to identify
Candida isolates. In an Iranian study by Shokohi et al. (21),
Candida species were identified in cancer patients by PCRRFLP using two restriction enzymes. In a similar study,
Mirhendi et al. (22) developed a one-enzyme PCR-RFLP
assay for the identification of six medically important
Candida species. Irobi et al. (23) used RFLP to differentiate
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Figure 6. Nucleotide changes (blue area is the restriction point identified by MwoI) detected in six C. albicans isolates that underwent
sequence analysis after comparison with the C. albicans strains downloaded from GenBank.

C. albicans, C. tropicalis, C. dubliniensis, and C. krusei
from 114 Candida isolates and 65 reference strains. Pinto
et al. (24) easily identify Candida spp. on the basis of size
and number of bands by using eight restriction enzymes.
Vijayakumar et al. (18) identified Candida species with
PCR-RFLP by using MspI restriction enzymes. Five species
of Candida were detected from the blood isolates of ICU
patients in that study.

In another study, ITS1, 5.8S, and ITS2 rDNA regions
were amplified in order to identify Candida species by PCR,
resulting in 480-bp and 929-bp PCR products. Restriction
with MwoI yielded bands of similar size for C. tropicalis, C.
parapsilosis, C. guilliermondii, and C. membranaefaciens;
the BslI enzyme was used to distinguish these species.
In this study MwoI formed a band pattern that allowed
the differentiation of twelve Candida species. Moreover,
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Figure 7. Nucleotide changes identified in four sequenced C. guilliermondii isolates after comparison with the C. guilliermondii and C.
membranaefaciens strains downloaded from GenBank.

the MwoI enzyme led to the definite identification of C.
albicans and C. dubliniensis. Remaining unidentified
species were defined by the BslI enzyme (13). In our study,
we found the same band pattern for nos. 99 and 139 C.
guilliermondii strains and the C. membranaefaciens ATCC
201377 standard strain. We also found the same band
patterns for C. parapsilosis, C. tropicalis, C. glabrata, C.
kefyr, C. krusei, and C. guilliermondii but different band
patterns for C. albicans strains having point mutation by
using two enzymes.
C. membranaefaciens was first isolated in 2005
from a non-Hodgkin lymphoma patient’s blood culture
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and catheter (25). Phenotypically and biochemically,
C. membranaefaciens and C. guilliermondii have been
reported to have many similarities, including their
microscopic morphology, formation of pink to purple
colonies on CHROMagar Candida medium, and inability
to form germ tubes in serum. In many previous studies,
these two species failed to be distinguished correctly (26).
In our study, isolates identified as C. guilliermondii were
isolated from blood and synovial fluid culture.
As the virulence of the Candida spp. isolated from
different locations is varied, rapid and reliable identification
methods are crucial for efficient antifungal treatments. The
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Figure 8. Dendrogram obtained after phylogenetic analysis of four sequenced C. guilliermondii isolates and
the C. guilliermondii and C. membranaefaciens sequences from GenBank.
Table 1. Size of ITS1-ITS2 products for Candida species before and after digestion with MwoI and BslI.
Candida
species (n)

Size of
ITS1-5.8S-ITS2 product (bp)

Size of
REA products with MwoI (bp)

Size of
REA products with BslI (bp)

C. albicans (40)

586

141, 84, 261
(36)

184, 141, 165, 95
(4)

C. parapsilosis (27)

570

336, 146, 88

C. tropicalis (26)

576

325, 154, 97

C. glabrata (25)

925

414, 174, 171, 86, 80

C. kefyr (11)

800

370, 430

C. krusei (10)

560

289, 134, 83, 54

C. guilliermondii (7)

657

355, 302 (5)

early diagnosis of invasive fungal infections is necessary to
decrease mortality. The primarily used yeast identification
procedures such as germ tube production, morphology
on Corn Meal Agar with Tween 80, and biochemical
identification are reported to be laborious and timeconsuming (16), as well as needing experience. Molecular
techniques are a good alternative for the identification
and diagnosis of fungi such as Candida spp. because they

390, 300 (2)

may provide rapid results with less work. Although DNA
sequence analysis can be considered as the gold standard
for accurate species identification, it is not widely available
in clinical laboratories and it is relatively expensive.
Numerous studies regarding the use of PCR-REA of ITS
rDNA as a rapid, easy, and cost-effective method for the
identification of Candida species have been reported (13–
16). MALDI-TOF MS is a recently discovered powerful
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Table 2. The sensitivity, specificity, and positive and negative predictive values of REA performed by MwoI and BslI enzyme for Candida
species.
REA with MwoI enzyme
Sensitivity (CI) (%)

Specificity (CI) (%)

Positive predictive
values (CI) (%)

Negative predictive
values (CI) (%)

C. albicans

90 (75.4–96.7)

100 (95.6–100.0)

100 (88.0–100.0)

96.4 (90.4–98.8)

C. glabrata

100 (83.4–100.0)

100 (96.2–100.0)

100 (83.4–100.0)

100 (96.2–100.0)

C. krusei

100 (65.5–100.0)

100 (96.6–100.0)

100 (65.5–100.0)

100 (96.6–100.0)

C. kefyr

100 (67.9–100.0)

100 (96.6–96.7)

100 (67.9–96.7)

100 (96.6–96.7)

C. parapsilosis

100 (84.5–100.0)

78.2 (69.5–85.0)

50.9 (37.0–64.7)

100 (96.6–100.0)

C. tropicalis

100 (84.0–100.0)

81.5 (74.1–87.3)

49.1 (35.3–63.0)

100 (96.1–100.0)

C. guilliermondii

100 (46.3–100.0)

98.6 (94.5–99.8)

71.4 (30.3–94.9)

100 (96.7–100.0)

C. parapsilosis

100 (84.5–100.0)

100 (96.1–100.0)

100 (84.5–100.0)

100 (96.1–100.0)

C. tropicalis

88.5 (68.7–97.0)

100 (96.1–100.0)

100 (82.2–100.0)

97.6 (92.5–99.4)

100 (96.1–100.0)

100 (84.0–100.0)

100 (96.1–100.0)

REA with BslI enzyme

REA with BslI after dilution of PCR products
C. tropicalis

100 (84.0–100.0)

CI: Confidence interval.

tool that has been reported to identify yeasts rapidly and
accurately; however, its high setup cost and requirement for
a useful database are major limitations of this method.
In our study, it was detected that PCR-REA was an
easy, rapid, and highly valuable tool that could be used in
routine diagnostic laboratories to identify Candida isolates
obtained from systemic specimens. Since the methods
used in this study are easy to perform and require only
standard molecular biology equipment, it is applicable in
routine diagnostic laboratories. C. albicans, C. krusei, C.
guilliermondii, C. kefyr, C. glabrata, C. tropicalis, and C.
parapsilosis sensitivities, specificities, positive predictive
values, and negative predictive values for MwoI were 90%,
100%, 100%, and 100%; 100%, 100%, 100%, and 100%;
100%, 98.6%, 71.4%, and 100%; 100%, 100%, 100%, and
100%; 100%, 100%, 100%, and 100%; 100%, 81.5%, 49.1%,
and 100%; and 100%, 78.2%, 50.9%, and 100%, respectively.
C. tropicalis and C. parapsilosis sensitivities, specificities,
positive predictive values, and negative predictive values for
BslI were 88.5%, 100%, 100%, and 100% and 100%, 100%,
100%, and 100%, respectively (Table 2). Another advantage
of this method compared to other molecular methods is

the speed of species identification. The whole procedure of
PCR-REA from Candida isolates can be completed within
33–34 h as compared to 48–72 h needed for phenotypic
identification methods.
Accurate identification of Candida strains is of critical
importance for prognostic, epidemiological, and therapeutic
purposes. Conventional methods are currently accepted as
the gold standard for the identification of Candida strains.
It is suggested that the REA method should be used for the
rapid identification of Candida species. It should also be used
where Candida species cannot be identified by conventional
methods. However, it should be kept in mind that REA
methods still have some limitations, such as variations
among the species. Molecular methods are not yet in a
position to take the place of the conventional gold-standard
methods but may bring additional benefits to conventional
identification methods in terms of speed and accuracy.
It can be concluded that restriction enzyme analysis with
MwoI and BslI enzymes can be used for the identification
of Candida species that require rapid identification or
for which identification by conventional methods is
problematic.

References
1.

Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology
of sepsis in the United States from 1979 through 2000. N Engl
J Med 2003; 348: 1546-1554.

1066

2.

Quindós G. Epidemiology of candidaemia and invasive
candidiasis. A changing face. Rev Iberoam Micol 2014; 31: 4248.

YİŞ and DOLUCA / Turk J Med Sci
3.

Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med
2015; 373: 1445-1456

16.

Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer
S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality
of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:
1172-1177.

Alam MZ, Alam Q, Jiman-Fatani A, Kamal MA, Abuzenadah
AM, Chaudhary AG, Akram M, Haque A. Candida
identification: a journey from conventional to molecular
methods in medical mycology. World J Microbiol Biotechnol
2014; 30: 1437-1451

4.

17.

5.

Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C,
Garbino J, Calandra T, Glauser MP, Täuber MG, Pittet D et al.
Epidemiology of candidemia in Swiss tertiary care hospitals:
secular trends, 1991–2000. Clin Infect Dis 2004; 38: 311-320.

Tekeli A, Akan OA, Koyuncu E, Dolapci I, Uysal S. Initial
Candida dubliniensis isolate in Candida spp. positive
haemocultures in Turkey between 2001 and 2004. Mycoses
2006; 49: 60-64.

18.

6.

Vallabhaneni S, Mody RK, Walker T, Chiller T. The global
burden of fungal diseases. Infect Dis Clin N Am 2016; 30: 1-11.

7.

Concia E, Azzini AM, Conti M. Epidemiology, incidence
and risk factors for invasive candidiasis in high-risk patients.
Drugs 2009; 69: 5-14.

Vijayakumar R, Giri S, Kindo A. Molecular species
identification of Candida from blood samples of intensive care
unit patients by polymerase chain reaction: restricted fragment
length polymorphism. J Lab Phys 2012; 4: 1.

19.

8.

J. Guinea. Global trends in the distribution of Candida species
causing candidemia. Clin Microbiol Infect 2014; 20: 5-10.

Khodadadi H, Karimi L, Jalalizand N, Adin H, Mirhendi H.
Utilization of size polymorphism in ITS1 and ITS2 regions
for identification of pathogenic yeast species. J Med Microbiol
2017; 66: 126-133.

9.

Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli
S, Muhlethaler K, Pfyffer G, Ruef C, Fehr J, Zbinden R et al.
Candida species distribution and antifungal susceptibility
testing according to European Committee on Antimicrobial
Susceptibility Testing and new vs. old Clinical and Laboratory
Standards Institute clinical breakpoints: a 6-year prospective
candidaemia survey from the fungal infection network of
Switzerland. Clin Microbiol Infect 2014; 20: 698-705

20.

Williams DW, Wilson MJ, Lewis MA, Potts AJ. Identification
of Candida species by PCR and restriction fragment length
polymorphism analysis of intergenic spacer regions of
ribosomal DNA. J Clin Microbiol 1995; 33: 2476-2479.

21.

Shokohi T, Soteh MB, Saltanat Pouri Z, Hedayati MT, Mayahi
S. Identification of Candida species using PCR-RFLP in cancer
patients in Iran. Indian J Med Microbiol 2010; 28: 147-151.

22.

Mirhendi H, Makimura K, Khoramizadeh M, Yamaguchi
H. A one-enzyme PCR-RFLP assay for identification of six
medically important Candida species. Jpn J Med Mycol 2006;
47: 225-229.

23.

Irobi J, Schoofs A, Goossens H. Genetic identification of
Candida species in HIV-positive patients using the polymerase
chain restriction fragment length polymorphism analysis of its
DNA. Mol Cell Probes 1999; 13: 401-406.

24.

Pinto PM, Resende MA, Koga-Ito CY, Ferreira JA, Tendler
M. rDNA-RFLP identification of Candida species in
immunocompromised and seriously diseased patients. Can J
Microbiol 2004; 50: 504-520.

25.

Fanci R, Pecile P. Central venous catheter-related infection
due to Candida membranaefaciens, a new opportunistic azoleresistant yeast in a cancer patient: a case report and a review of
literature. Mycoses 2005; 48: 357-359.

26.

Aghili SR, Shokohi T, Boroumand MA, Hashemi Fesharaki
S, Salmanian B. Intravenous catheter-associated candidemia
due to Candida membranaefaciens: the first Iranian case. J
Tehran Heart Cent 2015; 10: 101-105.

10.

11.

12.

Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes
Giannini MJ. Candida species: current epidemiology,
pathogenicity, biofilm formation, natural antifungal products
and new therapeutic options. J Med Microbiol 2013; 62: 10-24.
Peman J, Bosch M, Canton E, Viudes A, Jarque I, GómezGarcía M, García-Martínez JM, Gobernado M. Fungemia due
to Candida guilliermondii in a pediatric and adult population
during a 12-year period. Diagn Microbiol Infect Dis 2008; 60:
109-112.
Peman J, Zaragoza R. Current diagnostic approaches to
invasive candidiasis in critical care settings. Mycoses 2010; 53:
424-433.

13.

Trost A, Graf B, Eucker J, Sezer O, Possinger K, Göbel UB,
Adam T. Identification of clinically relevant yeasts by PCR/
RFLP. J Microbiol Meth 2004; 56: 201-211.

14.

Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang
TC. Identification of medically important yeast species by
sequence analysis of the internal transcribed spacer regions. J
Clin Microbiol 2006; 44: 693-699.

15.

Cassagne C, Cella AL, Suchon P, Normand AC, Ranque
S, Piarroux R. Evaluation of four pretreatment procedures for
MALDI-TOF MS yeast identification in the routine clinical
laboratory. Med Mycol 2013; 51: 371-377.

1067

